Glaxosmithkline pharmaceuticals headquarters in Brentford, west London

In response to challenges from the Federal Trade Commission, at least three pharmaceutical companies have asked to remove their patents from the Food and Drug Administration's Orange Book, which records patents on branded drugs and serves as a reference for generic manufacturers. The move by drugmakers could essentially accelerate the approval of generic versions of the drugs.

In November, the FTC sent warning letters to 10 medical device companies and drugmakers disputing the accuracy or relevance of more than 100 patents found in the book. Many of the patents at issue were for asthma inhalers, epinephrine autoinjectors and other drug products that may lead to delayed generic competition.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
Core and Group Health
Health Care Reform
Employee Participation
Employee-Paid
Employer-Paid